Skip to content

Study · Non-randomized trial · n = 10 · 2001

7 results

Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men.

Hislop MS, St Clair Gibson A, Lambert MI, Noakes TD, Marais AD

Atherosclerosis1 Dec 2001Cited by 19 (Europe PMC)

PMID11730823 (opens in a new tab)DOI10.1016/s0021-9150(01)00519-6 (opens in a new tab)PepBankPUB-11730823
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, triptorelin significantly reduced testosterone from 7.32 to 1.15 ng/ml.

    In plain wordsIn healthy men, triptorelin reduced testosterone compared with pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTestosterone concentration
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Measurements

    Testosterone
    7.32 ng/ml
    pretreatment
    Testosterone
    1.15 ng/ml
    triptorelin treatment

    Source sentences

    Summary
    Testosterone concentration was significantly reduced on triptorelin from 7.32+/-1.92 to 1.15+/-0.57 ng/ml (P=0.002).
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy men, triptorelin increased total cholesterol from 4.8 to 5.2 mmol/l.

    In plain wordsIn healthy men, triptorelin increased total cholesterol compared with pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTotal cholesterol
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Measurements

    Total cholesterol
    4.8 mmol/l
    pretreatment
    Total cholesterol
    5.2 mmol/l
    triptorelin treatment

    Source sentences

    Summary
    In the triptorelin group, mean total cholesterol, HDLC and Lp(a) were increased from 4.8+/-0.8 mmol/l to 5.2+/-1.0 mmol/l (P=0.039), 1.1+/-0.2 to 1.4+/-0.3 mmol/l (P=0.002) and 278+/-149 to 377+/-222 U/l (P=0.004) respectively.
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy men, triptorelin increased HDL cholesterol from 1.1 to 1.4 mmol/l.

    In plain wordsIn healthy men, triptorelin increased HDL cholesterol compared with pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseHDL cholesterol
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Measurements

    HDL cholesterol
    1.1 mmol/l
    pretreatment
    HDL cholesterol
    1.4 mmol/l
    triptorelin treatment

    Source sentences

    Summary
    In the triptorelin group, mean total cholesterol, HDLC and Lp(a) were increased from 4.8+/-0.8 mmol/l to 5.2+/-1.0 mmol/l (P=0.039), 1.1+/-0.2 to 1.4+/-0.3 mmol/l (P=0.002) and 278+/-149 to 377+/-222 U/l (P=0.004) respectively.
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy men, triptorelin increased lipoprotein(a) from 278 to 377 U/l.

    In plain wordsIn healthy men, triptorelin increased lipoprotein(a) compared with pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseLipoprotein(a)
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Measurements

    Lipoprotein(a)
    278 U/l
    pretreatment
    Lipoprotein(a)
    377 U/l
    triptorelin treatment

    Source sentences

    Summary
    In the triptorelin group, mean total cholesterol, HDLC and Lp(a) were increased from 4.8+/-0.8 mmol/l to 5.2+/-1.0 mmol/l (P=0.039), 1.1+/-0.2 to 1.4+/-0.3 mmol/l (P=0.002) and 278+/-149 to 377+/-222 U/l (P=0.004) respectively.
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy men receiving triptorelin, mean LDL cholesterol did not change.

    In plain wordsIn healthy men receiving triptorelin, LDL cholesterol did not change from pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLDL cholesterol
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean LDLC concentration and PPT were unchanged.
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy men receiving triptorelin, mean postprandial triglyceridaemia did not change.

    In plain wordsIn healthy men receiving triptorelin, blood triglycerides after a meal did not change from pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePostprandial triglyceridaemia
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean LDLC concentration and PPT were unchanged.
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).
  7. 07HumanNon-randomized trialEfficacy outcome

    In men receiving triptorelin, LDL particle size increased in four, decreased in two and remained unchanged in four subjects.

    In plain wordsIn men receiving triptorelin, LDL particle size increased, decreased or remained unchanged compared with pretreatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    MixedLDL particle size
    Study

    n = 10

    Comparator
    Pretreatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 5 weeksAs given in this study (human).

    Measurements

    Subjects with increased LDL particle size
    4 subjects
    triptorelin group
    Subjects with decreased LDL particle size
    2 subjects
    triptorelin group
    Subjects with unchanged LDL particle size
    4 subjects
    triptorelin group

    Source sentences

    Summary
    LDL particle size increased in four, decreased in two, and was unchanged in four subjects.
    1 context sentence
    Summary · context
    The experimental groups comprised nine male bodybuilders who self-administered anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks, and 10 healthy men whose testosterone concentration had been reversibly suppressed for 5 weeks using the GnRH agonist triptorelin (Decapeptyl; D-Trp-6-LHRH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.